MRI in the diagnosis of rare casе of primary multiple malignant tumors: osteosarcoma and urothelial bladder cancer, prostate adenocarcinoma

MRI in the diagnosis of rare casе of primary multiple malignant tumors: osteosarcoma and urothelial bladder cancer, prostate adenocarcinoma

Grigorev E.G., Frolova I.G., Perelmuter V.M., Slonimskaya E.M., Usynin E.A., Fesik E.A., Goldberg V.E., Goldberg A.V.

To present the observation of a rare combination of tumor pathology of the bladder, demonstrating the capabilities of magnetic resonance imaging (MRI) in the diagnosis of pelvic tumors.

Materials and methods. Patient G., 68 years old, who complained about the presence of blood in the urine, pain in the abdomen and iliac region. A bladder tumor was suspected. Studies were performed: MRI of the pelvic organs in order to clarify the localization of education, the degree of invasion and planning for further treatment.

Results. The diagnosis of a bladder tumor is confirmed. Tumors with different histological structure, simulating invasion of the muscular layer of the bladder, are revealed.

Conclusion. The presented case confirms the key role of MRI in the diagnosis of pathology of the pelvic organs, in particular – tumors of the bladder, with the ability to assess the prevalence of the pathological process and treatment planning. However, given the diversity of possible histological variants, pathological confirmation is necessary for the final diagnosis.

Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences.

Tomsk, Russia.

 

Keywords: MRI, dynamic contrast enhancement, DWI, bladder tumor, sarcoma.


Corresponding author:  Grigoriev E.G., e-mail: Этот e-mail адрес защищен от спам-ботов, для его просмотра у Вас должен быть включен Javascript

 

For citation: Grigorev E.G., Frolova I.G., Perelmuter V.M., Slonimskaya E.M., Usynin E.A., Fesik E.A., Goldberg V.E., Goldberg A.V. MRI in the diagnosis of rare casе of primary multiple malignant tumors: osteosarcoma and urothelial bladder cancer, prostate adenocarcinoma. REJR 2019; 9(2):288-294. DOI:10.21569/2222-7415-2019-9-2-288-294.

.

Received:        27.04.19 Accepted:       15.05.19